ArticleCPT: pharmacometrics & systems pharmacology2014
Exposure-response modeling of clinical end points using latent variable indirect response models.
Article in CPT: pharmacometrics & systems pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis.Clinical and translational science · 2022Trial
- Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data.The AAPS journal · 2020Trial
- Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.Journal of pharmacokinetics and pharmacodynamics · 2018Trial
- Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.Journal of pharmacokinetics and pharmacodynamics · 2017Trial
- Visual predictive check of longitudinal models and dropout.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Role of Disease Progression Models in Drug Development.Pharmaceutical research · 2022Review
- Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.Pharmacology research & perspectives · 2021Article
- Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients.Frontiers in pharmacology · 2021Article
- Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents.The AAPS journal · 2020Article
- Applying Beta Distribution in Analyzing Bounded Outcome Score Data.The AAPS journal · 2020Article
- Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.CPT: pharmacometrics & systems pharmacology · 2020Article
- Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM.Journal of pharmacokinetics and pharmacodynamics · 2019Article
- On the Comparison of Methods in Analyzing Bounded Outcome Score Data.The AAPS journal · 2019Review
- Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Landmark and longitudinal exposure-response analyses in drug development.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Evaluation of estimation, prediction and inference for autocorrelated latent variable modeling of binary data-a simulation study.Journal of pharmacokinetics and pharmacodynamics · 2016Article
- Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.Journal of pharmacokinetics and pharmacodynamics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure-response modeling facilitates effective dosing regimen selection in clinical drug development, where the end points are often disease scores and not physiological variables. Appropriate models need to be consistent with pharmacology and identifiable from the time courses of available data. This article describes a general framework of applying mechanism-based models to various types of clinical end points. Placebo and drug model parameterization, interpretation, and assessment are discussed with a focus on the indirect response models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.